Clinical Trial Update: A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 2 study evaluating the safety and effectiveness of JNJ-16269110 (R256918) in overweight and obese a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Diseases
• Nutritional Disorders
• Obesity
• Overweight

Drugs mentioned

• JNJ-16269110 (R256918) (JNJ-16269110)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Obesity, Nutritional and Metabolic Diseases | Phase 2 | Status: COMPLETED